Abbott announced today new results of two analyses from a major Phase III study of Humira (adalimumab) in ankylosing spondylitis (AS).
The first analysis demonstrates the ability of Humira to maintain the reduction of signs and symptoms in AS patients at 12 weeks through 52 weeks of treatment. A second analysis demonstrates that Humira rapidly and significantly reduced pain and fatigue in patients with AS, an inflammatory disease of the spine and spinal joints, as early as two weeks compared with placebo and that the improvement was maintained for at least 24 weeks.
